Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.
Cancer registration
Cancer screening
Ganpro database
Hokushin region
Malignant pleural mesothelioma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
23
03
2021
accepted:
14
06
2021
pubmed:
30
6
2021
medline:
21
4
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
Malignant pleural mesothelioma (MPM) is a major occupational and environmental neoplasm. The purpose of this study was to validate the clinical and epidemiological factors, diagnosis, and initial treatment among MPM patients in the Hokushin region. We surveyed retrospective data from 152,921 cancer patients in 22 principal hospitals. A total of 166 MPM cases were newly diagnosed. These patients consisted of 136 men and 30 women, with a median age of 69 years. We estimated the incidence rate for MPM to be 0.55 cases per 100,000 person-years in this study. The ratio per 100,000 population-years was 0.39 in Fukui, 0.60 in Ishikawa, 1.02 in Toyama and 0.35 in Nagano. Forty-five patients were discovered when diagnosed incidentally in patients under observations for other diseases. Forty-six cases were diagnosed as localized disease, while 13 had accompanying regional lymph node metastasis. Furthermore, 44 cases showed infiltration into adjacent organs. A histo-cytological diagnosis was made in 164 cases (98.8%). A surgical approach, chemotherapy, and radiotherapy were performed for 33, 88, and 6 patients, respectively, while 44 patients (26.5%) received best supportive care. Multimodality therapy was conducted in just 3.0% of the MPM patients CONCLUSION: MPM has a tragically rapid progression if discovered under observations for other diseases. Workers in health-related fields should be on high alert for aggressive MPM. Better evaluation and multi-disciplinary approaches to MPM in these regions are needed to optimize multimodality therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pleural mesothelioma (MPM) is a major occupational and environmental neoplasm. The purpose of this study was to validate the clinical and epidemiological factors, diagnosis, and initial treatment among MPM patients in the Hokushin region.
METHODS
METHODS
We surveyed retrospective data from 152,921 cancer patients in 22 principal hospitals.
RESULTS
RESULTS
A total of 166 MPM cases were newly diagnosed. These patients consisted of 136 men and 30 women, with a median age of 69 years. We estimated the incidence rate for MPM to be 0.55 cases per 100,000 person-years in this study. The ratio per 100,000 population-years was 0.39 in Fukui, 0.60 in Ishikawa, 1.02 in Toyama and 0.35 in Nagano. Forty-five patients were discovered when diagnosed incidentally in patients under observations for other diseases. Forty-six cases were diagnosed as localized disease, while 13 had accompanying regional lymph node metastasis. Furthermore, 44 cases showed infiltration into adjacent organs. A histo-cytological diagnosis was made in 164 cases (98.8%). A surgical approach, chemotherapy, and radiotherapy were performed for 33, 88, and 6 patients, respectively, while 44 patients (26.5%) received best supportive care. Multimodality therapy was conducted in just 3.0% of the MPM patients CONCLUSION: MPM has a tragically rapid progression if discovered under observations for other diseases. Workers in health-related fields should be on high alert for aggressive MPM. Better evaluation and multi-disciplinary approaches to MPM in these regions are needed to optimize multimodality therapy.
Identifiants
pubmed: 34185142
doi: 10.1007/s00432-021-03699-z
pii: 10.1007/s00432-021-03699-z
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1153-1158Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397:375–386
doi: 10.1016/S0140-6736(20)32714-8
pubmed: 33485464
Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD (2015) Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer 88:344–348
doi: 10.1016/j.lungcan.2015.03.005
pubmed: 25863904
Bianchi C, Bianchi T (2014) Global mesothelioma epidemic: trend and features. Indian J Occup Environ Med 18:82–88
doi: 10.4103/0019-5278.146897
pubmed: 25568603
pmcid: 4280782
Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A et al (2021) Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol 22:190–197
doi: 10.1016/S1470-2045(20)30606-9
pubmed: 33450184
Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K et al (2012) National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 103:483–490
doi: 10.1111/j.1349-7006.2011.02165.x
pubmed: 22126592
pmcid: 7713624
Hasegawa S, Tanaka F (2008) Malignant mesothelioma: current status and perspective in Japan and the world. Gen Thorac Cardiovasc Surg 56:317–323
doi: 10.1007/s11748-007-0243-2
pubmed: 18607677
Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA et al (2013) Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008. Int J Occup Environ Health 19:1–10
doi: 10.1179/2049396712Y.0000000016
pubmed: 23582609
Kishimoto T, Gemba K, Fujimoto N, Aoe K, Kato K, Takeshima Y et al (2010) Clinical study on mesothelioma in Japan: relevance to occupational asbestos exposure. Am J Ind Med 53:1081–1087
doi: 10.1002/ajim.20868
pubmed: 20564517
Kurumatani N, Natori Y, Mizutani R, Kumagai S, Haruta M, Miura H et al (1999) A historical cohort mortality study of workers exposed to asbestos in a refitting shipyard. Ind Health 37:9–17
doi: 10.2486/indhealth.37.9
pubmed: 10052294
Lanphear BP, Buncher CR (1992) Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718–721
pubmed: 1494965
Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y (2001) Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 39:65–74
doi: 10.2486/indhealth.39.65
pubmed: 11341560
Murphy DC, Mount A, Starkie F, Taylor L, Aujayeb A (2020) A review of malignant pleural mesothelioma in a large North East UK pleural centre. Pleura Peritoneum 6:20200144
pubmed: 33506102
Pelucchi C, Malvezzi M, La Vecchia C, Levi F, Decarli A, Negri E (2004) The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 90:1022–1024
doi: 10.1038/sj.bjc.6601638
pubmed: 14997201
pmcid: 2409631
Price A (2011) What is the role of radiotherapy in malignant pleural mesothelioma? Oncologist 16:359–365
doi: 10.1634/theoncologist.2010-0185
pubmed: 21346022
pmcid: 3228097
Rice D (2011) Surgical therapy of mesothelioma. Recent Results Cancer Res 189:97–125
doi: 10.1007/978-3-642-10862-4_7
pubmed: 21479898
Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M et al (2014) Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 384:1118–1127
doi: 10.1016/S0140-6736(14)60418-9
pubmed: 24942631
Shintani Y, Hasegawa S, Takuwa T, Aoe K, Kato K, Fujimoto N et al (2018) Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study. J Thorac Dis 10:1968–1971
doi: 10.21037/jtd.2018.03.53
pubmed: 29707353
pmcid: 5906251
Uramoto H, Takiguchi T, Koizumi T, Tanimoto A, Hayashi R, Nakazawa Y, Ito KI, Nakada M, Hirono Y, Nishino Y, Yano S (2021) Multi-institutional survey of thymic carcinoma patients in Hokushin region. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-021-03620-8
doi: 10.1007/s00432-021-03620-8
pubmed: 34185142
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644
doi: 10.1200/JCO.2003.11.136
pubmed: 12860938
Waller DA, Opitz I, Bueno R, Van Schil P, Cardillo G, Harpole D et al (2021) Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. Eur J Cardiothorac Surg 59:8–11
doi: 10.1093/ejcts/ezaa363
pubmed: 33395697
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D et al (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–1414
doi: 10.1016/S0140-6736(15)01238-6
pubmed: 26719230